Targeted therapy in breast cancer (WP5496)

Homo sapiens

Open in new tab Open in Newt (SBGN)
Download PNG Download SVG Download JSON Download GPML Learn more about Downloads
"Trastuzumab and pertuzumab inhibit HER2 signaling by binding to the extracellular domain of HER2. Lapatinib, neratinib, tucatinib, and pyrotinib inhibit HER signaling by binding to the intracellular tyrosine kinase domain of the Her family members. EGFR epidermal growth factor receptor, HER human epidermal growth factor receptor, MEK MAP kinase kinase, ERK MAP kinase, PI3K phosphoinositide 3-kinases (adapted from “HER2 Signaling Pathway”, by BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates)". Source: Figure F1, https://pmc.ncbi.nlm.nih.gov/articles/PMC9281252/. Derived from PFOCR, https://pfocr.wikipathways.org/figures/PMC9281252__12032_2022_1749_Fig1_HTML.html.

Authors

Eric Weitz

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Annotations

Cell Type Ontology

mammary gland epithelial cell luminal epithelial cell of mammary gland

Pathway Ontology

drug pathway breast cancer pathway

Disease Ontology

breast cancer

Participants
Query Drugst.One

Label Type Compact URI Comment
Tucatinib Metabolite drugbank:DB11652
Lapatinib Metabolite chebi:49603
Neratinib Metabolite chebi:61397
Pyrotinib Metabolite drugbank:DB14993
Trastuzumab Metabolite drugbank:DB00072
Pertuzumab Metabolite drugbank:DB06366
KRAS GeneProduct ensembl:ENSG00000133703
HRAS GeneProduct ensembl:ENSG00000174775
NRAS GeneProduct ensembl:ENSG00000213281
RAF1 GeneProduct ensembl:ENSG00000132155
MAP2K1 GeneProduct ensembl:ENSG00000107356
MAP2K2 GeneProduct ensembl:ENSG00000101418
MAP2K3 GeneProduct ensembl:ENSG00000107958
MAP2K4 GeneProduct ensembl:ENSG00000115669
MAP2K5 GeneProduct ensembl:ENSG00000138015
MAP2K6 GeneProduct ensembl:ENSG00000129652
MAP2K7 GeneProduct ensembl:ENSG00000118907
PIK3CA GeneProduct ensembl:ENSG00000121879
PIK3CB GeneProduct ensembl:ENSG00000051382
PIK3CG GeneProduct ensembl:ENSG00000105851
PIK3CD GeneProduct ensembl:ENSG00000171608
PIK3R1 GeneProduct ensembl:ENSG00000145675
PIK3R2 GeneProduct ensembl:ENSG00000105647
PIK3R3 GeneProduct ensembl:ENSG00000117461
PIK3R4 GeneProduct ensembl:ENSG00000196455
PIK3R5 GeneProduct ensembl:ENSG00000141506
PIK3R6 GeneProduct ensembl:ENSG00000276231
PIK3C2A GeneProduct ensembl:ENSG00000011405
PIK3C2B GeneProduct ensembl:ENSG00000133056
PIK3C2G GeneProduct ensembl:ENSG00000139144
AKT1 GeneProduct ensembl:ENSG00000142208
AKT2 GeneProduct ensembl:ENSG00000105221
AKT3 GeneProduct ensembl:ENSG00000117020
MAPK1 GeneProduct ensembl:ENSG00000100030
MAPK3 GeneProduct ensembl:ENSG00000102882
EGFR GeneProduct ensembl:ENSG00000146648
ERBB2 GeneProduct ensembl:ENSG00000141736
ERBB3 GeneProduct ensembl:ENSG00000065361
ERBB4 GeneProduct ensembl:ENSG00000178568

References

  1. Molecular perspective on targeted therapy in breast cancer: a review of current status. Demir Cetinkaya B, Biray Avci C. Med Oncol. 2022 Jul 14;39(10):149. PubMed Europe PMC Scholia